• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy

by July 18, 2024
written by July 18, 2024

Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy.

Despite the setback, the company remains committed to exploring alternative pathways to bring this promising treatment to market.

The FDA’s recommendation came after Agenus presented results from its Phase 2 study, revealing a 19.4% overall response rate (ORR) and a 90% 6-month survival rate for the 75mg dosage of BOT/BAL.

However, concerns about the therapy’s survival benefits led to a sharp sell-off of Agenus stock, which had seen significant gains earlier in the year.

Dr. Steven O’Day, Agenus’ chief medical officer, emphasized the company’s determination to advance BOT/BAL, including plans to incorporate a BOT monotherapy arm in its upcoming Phase 3 trial.

This strategic move aims to address FDA concerns and pave the way for future regulatory approval.

Financial and analyst insights

Despite the stock’s recent downturn, analysts previously projected a bullish outlook for Agenus, with a consensus “buy” rating and an average price target of $39 per share.

The company’s financial resilience, including ending the first quarter with $52.9 million in cash, underscores its ability to navigate regulatory challenges while advancing its clinical pipeline.

Agenus to meet with European regulators

Looking ahead, Agenus plans strategic engagements with European regulators in the third quarter of 2024 to discuss regulatory pathways for BOT/BAL.

Additionally, the company will present compelling data on the therapy’s efficacy in treating Sarcoma at a prestigious European medical oncology event in September, highlighting its commitment to addressing unmet medical needs.

The FDA’s decision represents a critical juncture for Agenus as it strives to balance scientific innovation with regulatory scrutiny.

While the setback underscores the challenges inherent in drug development, Agenus remains steadfast in its mission to deliver innovative treatments that can potentially transform patient outcomes in oncology.

The post Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Netflix Q2 earnings preview: Wall Street awaits updates on ad-supported model
next post
Domino’s Pizza stock crashes as American consumer struggles with rising food prices

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Number of injunctions halting Trump policies trounces predecessors by double

    March 17, 2025
  • White House: US will lead in AI, but China is catching up

    April 8, 2025
  • Russia remains ‘active threat’ in influencing 2024 election, likely to focus on swing states: U.S. officials

    November 5, 2024
  • China controls over 80% of battery materials crucial to US defense equipment, unsettling report reveals

    July 23, 2025
  • Trump picks Steven Cheung for communications director, Sergio Gor for personnel office director

    November 15, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,279)
  • Investing (634)
  • Stock (935)

Latest Posts

  • Most Americans reject push by Biden, Dems to change Supreme Court: poll

    August 21, 2024
  • Fetterman hails Rubio as ‘strong choice’ for secretary of state, says he will vote to confirm him

    November 12, 2024
  • Senate to debate Trump’s $9B clawback bill after dramatic late-night votes

    July 16, 2025

Recent Posts

  • Trump team ‘confident’ Senate Republicans will approve cabinet selections

    November 21, 2024
  • ‘Efficient and accountable’: GOP-led DOGE bill aims to slash outflow of federal dollars

    November 21, 2024
  • Zelenskyy downplays comment that Trump doesn’t know how to end Russia’s war with Ukraine

    September 27, 2024

Editor’s Pick

  • Trump claims Putin, Xi, Kim are conspiring against the US after military parade in China

    September 3, 2025
  • Israeli cabinet backs Trump’s demand for Hamas to release all hostages by Saturday deadline

    February 11, 2025
  • Trump signs executive order to end collective bargaining at agencies involved with national security

    March 28, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock